Surrozen, Inc. (SRZN) Insider Trading

Last 12 months

Insiders bought $5.98M and sold $325k on the open market.

None of the selling was scheduled in advance under a 10b5-1 plan. Chief Executive Officer Craig C Parker sold $151k on May 4, 21% of their stake, outside a plan.

Net open-market

+$5.66M

5 buys · 5 sales

Under a 10b5-1 plan

of the value sold

Insiders who bought / sold

1 / 3

executives and directors

Last open-market buy

Jan 2026

Jan 20, 2026

Get an email when SRZN's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Jul 22	Chen-Ming Yu Large holder	SoldNo plan 2 parts	325,000	$21.25 average	$6.91M	36%	Form 4
May 4	Yang Li Exec. Vice President, Research	SoldNo plan	1,584	$33.33	$53k	8.1%	Form 4
May 4	Charles O Williams Chief Operating Officer	SoldNo plan	2,036	$33.33	$68k	11%	Form 4
May 4	Craig C Parker Chief Executive Officer	SoldNo plan	4,524	$33.33	$151k	21%	Form 4
Mar 23 – 24	TCG Crossover Fund II, L.p. Large holder	Bought 4 parts	121,881	$24.72 average	$3.01M	20%	Form 4
Mar 12 – 16	TCG Crossover Fund II, L.p. Large holder	Bought 6 parts	48,997	$24.91 average	$1.22M	7.8%	Form 4
Feb 11 – 12	TCG Crossover Fund II, L.p. Large holder	Bought 4 parts	18,856	$23.60 average	$445k	3.0%	Form 4
Jan 30 – Feb 3	TCG Crossover GP Iii, LLC Large holder	Bought 6 parts	9,357	$21.65 average	$203k	1.5%	Form 4
Jan 15 – 20	Column Group Opportunity III GP, LP Large holder	Bought 6 parts	32,507	$19.74 average	$642k	1.5%	Form 4
Jan 15 – 20	Tim Kutzkey Director	Bought 6 parts	32,507	$19.74 average	$642k	1.5%	Form 4
Jan 13 – 14	Tim Kutzkey Director	Bought 4 parts	17,993	$19.86 average	$357k	0.8%	Form 4
Jan 13 – 14	TCG Opportunity III GP, LLC Large holder	Bought 4 parts	17,993	$19.86 average	$357k	0.8%	Form 4
Jan 6	Column Group III GP, LP Large holder	Bought 2 parts	15,100	$19.89 average	$300k	0.7%	Form 4
Jan 6	Tim Kutzkey Director	Bought 2 parts	15,100	$19.89 average	$300k	0.7%	Form 4
Jan 5	Yang Li Exec. Vice President, Research	SoldNo plan	1,118	$19.87	$22k	6.2%	Form 4
Jan 5	Charles O Williams Chief Operating Officer	SoldNo plan	1,566	$19.87	$31k	11%	Form 4
Dec 4, 2025 – Dec 5, 2025	Tim Kutzkey Director	Bought 4 parts	36,150	$19.22 average	$695k	1.7%	Form 4
Dec 4, 2025 – Dec 5, 2025	Column Group III GP, LP Large holder	Bought 4 parts	36,150	$19.22 average	$695k	1.7%	Form 4
Nov 13, 2025	Tim Kutzkey Director	Bought 2 parts	315,457	$12.65 average	$3.99M	17%	Form 4
Nov 13, 2025	Column Group III GP, LP Large holder	Bought 2 parts	315,457	$12.65 average	$3.99M	17%	Form 4
Mar 26, 2025	Column Group Opportunity Iii, LP Large holder	Bought 3 parts	1,034,482	$11.60 average	$12M	128%	Form 4
Jan 3, 2025	Yang Li Exec. Vice President, Research	SoldNo plan	843	$17.37	$15k	5.9%	Form 4
Jan 3, 2025	Charles O Williams CFO and COO	SoldNo plan	1,181	$17.37	$21k	12%	Form 4

Jul 22No plan
Chen-Ming Yu
Large holder · sold 325,000 at avg $21.25
$6.91M
36% of stake
May 4No plan
Yang Li
Exec. Vice President, Research · sold 1,584 at $33.33
$53k
8.1% of stake
May 4No plan
Charles O Williams
Chief Operating Officer · sold 2,036 at $33.33
$68k
11% of stake
May 4No plan
Craig C Parker
Chief Executive Officer · sold 4,524 at $33.33
$151k
21% of stake
Mar 23 – 24
TCG Crossover Fund II, L.p.
Large holder · bought 121,881 at avg $24.72
$3.01M
20% of stake
Mar 12 – 16
TCG Crossover Fund II, L.p.
Large holder · bought 48,997 at avg $24.91
$1.22M
7.8% of stake
Feb 11 – 12
TCG Crossover Fund II, L.p.
Large holder · bought 18,856 at avg $23.60
$445k
3.0% of stake
Jan 30 – Feb 3
TCG Crossover GP Iii, LLC
Large holder · bought 9,357 at avg $21.65
$203k
1.5% of stake
Jan 15 – 20
Column Group Opportunity III GP, LP
Large holder · bought 32,507 at avg $19.74
$642k
1.5% of stake
Jan 15 – 20
Tim Kutzkey
Director · bought 32,507 at avg $19.74
$642k
1.5% of stake
Jan 13 – 14
Tim Kutzkey
Director · bought 17,993 at avg $19.86
$357k
0.8% of stake
Jan 13 – 14
TCG Opportunity III GP, LLC
Large holder · bought 17,993 at avg $19.86
$357k
0.8% of stake
Jan 6
Column Group III GP, LP
Large holder · bought 15,100 at avg $19.89
$300k
0.7% of stake
Jan 6
Tim Kutzkey
Director · bought 15,100 at avg $19.89
$300k
0.7% of stake
Jan 5No plan
Yang Li
Exec. Vice President, Research · sold 1,118 at $19.87
$22k
6.2% of stake
Jan 5No plan
Charles O Williams
Chief Operating Officer · sold 1,566 at $19.87
$31k
11% of stake
Dec 4, 2025 – Dec 5, 2025
Tim Kutzkey
Director · bought 36,150 at avg $19.22
$695k
1.7% of stake
Dec 4, 2025 – Dec 5, 2025
Column Group III GP, LP
Large holder · bought 36,150 at avg $19.22
$695k
1.7% of stake
Nov 13, 2025
Tim Kutzkey
Director · bought 315,457 at avg $12.65
$3.99M
17% of stake
Nov 13, 2025
Column Group III GP, LP
Large holder · bought 315,457 at avg $12.65
$3.99M
17% of stake
Mar 26, 2025
Column Group Opportunity Iii, LP
Large holder · bought 1,034,482 at avg $11.60
$12M
128% of stake
Jan 3, 2025No plan
Yang Li
Exec. Vice President, Research · sold 843 at $17.37
$15k
5.9% of stake
Jan 3, 2025No plan
Charles O Williams
CFO and COO · sold 1,181 at $17.37
$21k
12% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch SRZN, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Related stocks: Biological Products, (No Diagnostic Substances)

RVMDRevolution Medicines Inc.

ELUTElutia Inc.

RLAYRelay Therapeutics Inc.

CRBUCaribou Biosciences, Inc.

LCTXLineage Cell Therapeutics Inc.

CRSPCrispr Therapeutics AG

ALECAlector Inc.

XFORX4 Pharmaceuticals Inc.

Spot a number that looks wrong? Check it in SRZN's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing SRZN

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.